Summit Therapeutics Reports Financial Results and Operationa

HARMONi and HARMONi-3 Enrollment Continues


Promising Intracranial Anti-Tumor Activity and Safety Data Featured at the 2024 European Lung Cancer Congress with Ivonescimab Alone or Combined with...

Related Keywords

Miami , Florida , United States , Japan , Canada , Spain , Cleveland Clinic , Sweden , California , South Korea , Germany , United Kingdom , China , Italy , Menlo Park , France , Stanford , Leicestershire , Australia , Stockholm , Han , Chinese , American , Mostafa Ronaghi , Drug Administration , Royal Institute Of Technology , Nasdaq , Stanford Genome Technology Center , Akeso Inc , Illumina Inc , International Agency For Research On Cancer , Us National Cancer Institute , Development Rd Expenses , American Cancer Society , Development Expense , World Health Organization , National Institute Of Health , Exchange Commission , Summit Therapeutics Inc , Japan National Cancer Registry , Development Expenses , Md Anderson Cancer Center , Summit Therapeutics , License Agreement , Executive Board Member , Chief Technology Officer , Principal Investigator , Royal Institute , Cash Equivalents , Restricted Cash , Nasdaq Global Market , Private Securities Litigation Reform Act , Consolidated Statements , Months Ended March , Consolidated Balance Sheet , Consolidated Statement , Cash Flows , Process Research , Loss Per Common , Loss Per Basic , Diluted Common Share , Per Basic , Diluted Common , Administrative Expenses , Critical Terms Contained , Death Ligand , Proportion Score , Response Assessment , Vascular Endothelial Growth Factor , Cancer Society , International Agency , Japan National Cancer , Cancer Epidemiology , Positive Lung Cancer , Endothelial Growth Factor , Its Receptor , Crucial Target , Cancer Institute , National Institute , Accessed April , Current Researches , Markets ,